| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.makerslabs.com | |
| Market Cap | 57.62 Cr. | |
| Enterprise Value(EV) | 58.56 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -8.60 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 118.51 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 0.82 | Calculated using Price: 97.50 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.59 Cr. | 5,900,376 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Makers Laboratories was incorporated in 1985. The company is promoted and managed by Ipca Laboratories group. The company is engaged in manufacturing pharmaceutical formulations and drug intermediaries. The company's plants are located in Palghar and Dombivli in Thane (Maharashtra). The company has a prominent presence in the therapeutic segment of antibiotics. | ||
| 1 Day |
|
-3.51% |
| 1 Week |
|
-5.02% |
| 1 Month |
|
-5.34% |
| 3 Month |
|
-19.52% |
| 6 Month |
|
-29.81% |
| 1 Year |
|
-46.60% |
| 2 Year |
|
-57.53% |
| 5 Year |
|
+38.83% |
| 10 Year |
|
+456.82% |
| 2 years | 2021-03 | 2022-03 | |
| Return on Equity (%) | 2.49 | 20.61 | |
| Return on Capital Employed (%) | 6.53 | 24.00 | |
| Return on Assets (%) | 0.99 | 8.35 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 54 | 60 | 72 | |
| Non Curr. Liab. | 17 | 13 | 11 | |
| Curr. Liab. | 33 | 33 | 33 | |
| Minority Int. | 32 | 39 | 39 | |
| Equity & Liab. | 136 | 144 | 156 | |
| Non Curr. Assets | 75 | 81 | 87 | |
| Curr. Assets | 61 | 63 | 68 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 136 | 144 | 156 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 69 | 127 | 99 | |
| Other Income | 1 | 3 | 3 | |
| Total Income | 70 | 130 | 102 | |
| Total Expenditure | -61 | -108 | -96 | |
| PBIDT | 9 | 21 | 6 | |
| Interest | -2 | -2 | -2 | |
| Depreciation | -5 | -4 | -4 | |
| Taxation | -1 | -4 | -2 | |
| Exceptional Items | 0 | 0 | ||
| PAT | 1 | 12 | -2 | |
| Minority Interest | -2 | -7 | -3 | |
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | 0 | 5 | -5 | |
| Adjusted EPS | -1 | 10 | -9 |
| Particulars | 2 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | ||
| Cash Fr. Inv. | -12 | ||
| Cash Fr. Finan. | 0 | ||
| Net Change | -3 | ||
| Cash & Cash Eqvt | 2 |
|
Fri, 31 Mar 2023
Closure of Trading Window It is hereby notified that the trading window for dealing in the securities of the Company by the insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations 2015 shall remain closed with effect from close of business hours on 31st March 2023 and until 48 hours after the declaration of the Companys audited financial results for the 4th quarter and financial year ended 31st March 2023 . |
|
Wed, 08 Mar 2023
Announcement under Regulation 30 (LODR)-Credit Rating This is to inform you that CARE Edge Ratings has re-affirmed the ratings to the Companys long term bank facilities |
|
Mon, 27 Feb 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 kindly note that the Company has issued duplicate share certificate(s) to the following shareholder in lieu of the original share certificate misplaced / lost as per the attached file |
| Fri, 31 Mar 2023 |
High Delivery Percentage
|
Close Crossing Last Week Low
|
Opening at Low
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors